Claims for Patent: 6,916,813

Summary for Patent: 6,916,813

Title:	(1-phenyl-2-heteoaryl)ethyl-guanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase
Abstract:	Compounds having the formula (I), and pharmaceutically acceptable salts thereof, ##STR1## are useful for modulating mitochondrial F.sub.1 F.sub.0 ATPase activity and treating ischemic conditions including myocardial infarction, congestive heart failure, and cardiac arrhythmias.
Inventor(s):	Atwal; Karnail S. (Pennington, NJ), Grover; Gary J. (Stockton, NJ), Ding; Charles Z. (Dallas, TX), Stein; Philip D. (Pennington, NJ), Lloyd; John (Yardley, PA), Ahmad; Saleem (Wall, NJ), Hamann; Lawrnce G. (Cherry Hill, NJ), Green; David (Haverhill, MA), Ferrara; Francis N. (Bedminster, NJ)
Assignee:	Bristol-Myers Squibb Co. (Princeton, NJ)
Application Number:	10/315,818
Patent Claims:	1. A compound having the formula (I): ##STR575## or a pharmaceutically-acceptable salt or hydrate, thereof, wherein: R.sub.1 is cyano, --SO.sub.2 R.sub.8, --C(.dbd.O)R.sub.9, or heteroaryl; R.sub.2 is (i) independently hydrogen, alkyl, or substituted alkyl, or (ii) taken together with R.sub.3 forms a heterocyclo; R.sub.3 is (i) independently alkyl, substituted alkyl, alkylthio, aminoalkyl, carbamyl, A-aryl, A-heterocyclo, A-heteroaryl, or A-cycloalkyl, or (ii) taken together with R.sub.2 forms a heterocyclo; Z is heteroaryl provided that when R.sub.1 is cyano, Z is not 2-pyridinyl; A is a bond, C.sub.1-4 alkylene, C.sub.2-4 alkenylene, substituted C.sub.1-4 alkylene, substituted C.sub.2-4 alkenylene, --C(.dbd.O)NR.sub.19 --, --C.sub.1-4 alkylene-C(.dbd.O)NR.sub.19 --, or substituted C.sub.1-4 alkylene-C(.dbd.O)NR.sub.19 --: R.sub.4 at each occurence is selected independently of each other R.sub.4 from the group consisting of halogen, alkyl, substituted akyl, haloalkyl, nitro, cyano, haloalkoxy, OR.sub.25, SR.sub.25, NR.sub.25 R.sub.26, NR.sub.25 SO.sub.2 R.sub.27, SO.sub.2 R.sub.27, SO.sub.2 NR.sub.25 R.sub.26, CO.sub.2 R.sub.26, C(.dbd.O)R.sub.26, C(.dbd.O)NR.sub.25 R.sub.26, OC(.dbd.O)R.sub.25, --OC(.dbd.O)NR.sub.25 R.sub.26, NR.sub.25 C(.dbd.O)R.sub.26, NR.sub.25 CO.sub.2 R.sub.26, aryl, heteroaryl, heterocyclo and cycloalkyl; R.sub.9 is --NR.sub.10 R.sub.11, alkyl, substituted alkyl, alkoxy, alkylthio, cyoloalkyl, aryl, heteroaryl, heterocyclo, or --CO.sub.2 R.sub.12 ; R.sub.10 and R.sub.11 are (i) independently selected from hydrogen, alkyl, substituted alkyl, alkoxy, heterocyclo, cycloalkyl, aryl, and heteroaryl;or (ii) taken together form a heterocyclo or heteroaryl; R.sub.12 and R.sub.19 are hydrogen or alkyl; R.sub.25 and R.sub.26 are independently selected from hydrogen, alkyl, or substitizted alkyl, or taken together form a heterocyclo or heteroaryl ring; R.sub.27 is alkyl or substituted alkyl, and q is 0, 1, 2, or 3. 2. The compound of claim 1, or a pharmaceutically-acceptable salt or hydrate, thereof, in which Z is an optionally-substituted bicyclic heteroaryl. 3. The compound of claim 1, or a pharmaceutically-acceptable salt or hydrate, thereof, in which: Z is triazolyl optionally substituted with one to two R.sub.7 or imidazolyl optioiially substituted with one to two R.sub.7 and/or having fused thereto a benzene ring in turn optionally substituted with one to two R.sub.7 ; and R.sub.7 is alkyl, carbamyl, or substituted alkyl. 4. The compound of claim 1, or a pharmaceutically-acceptable salt or hydrate, thereof, in which R.sub.1 is cyano or --C(.dbd.O)R.sub.9. 5. The compound of claim 1 or a pharmaceutically-acceptabl salt or hydrate, thereof, in which R.sub.1 is cyano, --SO.sub.2 R.sub.8, --C(.dbd.O)R.sub.9, or thiazolyl; R.sub.8 is C.sub.1-4 alkyl or phenyl optionally substituted with alkyl, halogen, haloalkoxy, cyano, nitro, or trifluoromethyl; R.sub.9 is a) NR.sub.10 R.sub.11 ; b) C.sub.1-4 alkyl optionally substituted with one to two of: i) SR.sub.13, OR.sub.13, NR.sub.13a R.sub.13b, halogen, trifluoromethyl, CO.sub.2 R.sub.13a, and C(.dbd.O)NR.sub.13a R.sub.13b ; ii) cycloalkyl optionally substituted with one to two of C(.dbd.O)H, C.sub.1-4 acyl, alkenyl, carbamyl, and/or phenyl in turn optionally substituted with halogen; iii) phenyl or napthyl optionally substituted with one to two of halogen, nitro, amino, alkyl, hydroxy, C.sub.1-4 alkoxy, or having fused thereto a five or six membered heterocyclo; iv) pyridinyl, thiophenyl, furanyl, tetrahydrofuranyl, or azepinyl, optionally substituted with alkyl or having fused thereto a five to six membered carbocyclic ring optionally substituted with keto or C.sub.1-4 alkoxy; c) C.sub.1-4 alkoxy; d) C.sub.1-4 alkylthio; e) CO.sub.2 alkyl; i) 3 to 6 membered cycloalkyl optionally having up to four substituetits selected from alkyl, halogen, cyano, alkenyl, acyl, alkylthio, carbamyl, phenyl in turn optionally substituted with halogen; or having an aryl fused thereto; g) pheuyl optionally substituted with one to four of halogen, cyano, trifluoromethyl, nitro, hydroxy, C.sub.1-4 alkoxy, haloalkoxy, C.sub.1-4 alkyl, CO.sub.2 alkyl, SO.sub.2 alkyl, SO.sub.2 NH.sub.2, amino NH(C.sub.1-4 alkyl), N(C.sub.1-4 alkyl).sub.2, NHC(.dbd.O)alkyl, C(.dbd.O)alkyl, and/or C.sub.1-4 alkyl optionally substituted with one to three of trifluoromethyl, hydroxy, cyano, phenyl, pyridinyl; and/or a five or six membejed heteroaryl or heterocyle in turn optionally substituted with keto or having a benzene ring fused thereto; h) pyridinyl, thiazolyl, furanyl, thiophenyl, and pyrrolyl optionally substituted with one to two of halogen, alkyl, and phenyl in turn optionally substituted with halogen or trifluoromethyl; R.sub.10 and R.sub.11 are a) independently selected from: i) hydrogen, C.sub.1-4 alkoxy, heterocyolo, cycloalkyl, aryl, and heteroaryl; and ii) C.sub.1-4 alkyl optionally substituted with one to two of --CO.sub.2 alkyl, --C(.dbd.O)NH(aryl), NH(aryl), cycloalkyl, phenyloxy, phenyl in turn optionally substituted with C.sub.1-4 alkyl, hydroxy, C.sub.1-4 alkoxy, halogen, amino, nitro, tetrahydrofuranyl, and/or five or six incrnbered heterocyclo, or having a five or six membered heterocyclo fused thereto; pyrrolidinyl optionally substituted with keto; napthyl, anthracenyl, pyridinyl, thiophenyl, furanyl, imidazolyl, benzimidazolyl, or indolyl in turn optionally substituted with C.sub.1-4 alkyl or C.sub.1-4 alkoxy; or b) R.sub.10 and R.sub.11 taken together form a heterocyclo selected from pyrrolidinyl, piperazinyl, piperidinyl, morpholinyl, tetrahydropyridinyl, and imidazoilidinyl, wherein said heterocyclo formed by R.sub.10 and R.sub.11 is optionally substistuted with one to two of keto, CO.sub.2 H, C.sub.14 alkoxy, CO.sub.2 alkyl, C.sub.1-4 carbamyl, benzyl; phenyl in turn optionally substituted with alkyl, halogen, or C.sub.1-4 alkoxy; tetrahydropyridinyl in turn optionally substituited with keto and/or phenyl; alkyl optionally substituted with amino or NHR.sub.21 wherein R.sub.21 is alkyl or phenyl optionally substituted with alkyl; and/or has a benzene ring fused thereto in turn optionally substituted with one to two of alkyl, C.sub.1-4 alkoxy, CO.sub.2 alkyl, and/or C.sub.1-4 carbamyl; R.sub.13 is hydrogen or alkyl; and R.sub.3a and R.sub.13b are selected from hydrogen, alkyl, and aryl. 6. The compound of claim 1, or a pharmaceutically-acceptable salt or hydrate, thereof, in which R.sub.2 is (i) independently hydrogen, alkyl, or substituted alkyl, or (ii) taken together with R.sub.3 forms a heterocyclo optionally substituted with alkyl or substituted alkyl; R.sub.3 is (i) independently selected from C.sub.1-4 alkyl, alkylthio, aminoalkyl, -A-aryl, -A-heterocyclo, -A-cycloalkyl, and -A-hetaroaryl, optionally having one to three substituents selected from R.sub.3a ; and/or having fused thereto a five or six membered carbocyclic ring, or (ii) taken together with R.sub.2 forms a heterocyclo optionally substituted with alkyl or substituted alkyl; R.sub.3a at each occurrence is selected independently from alkyl, substituted alkyl, halogen, haloalkoxy, cyano, nitro, keto, trifluoromethyl, --NR.sub.17 R.sub.18, --SR.sub.17, --OR.sub.17, --SO.sub.2 R.sub.17a, --SO.sub.2 NR.sub.17 R.sub.18, --NR.sub.17 C(.dbd.O)R.sub.18, --CO.sub.2 R.sub.17, --C(.dbd.O)R.sub.17, cyoloalkyl, aryl, heterocyolo, and heteroaryl, wherein when R.sub.3a is cycloalkyl, aryl, heterocyclo or heteroaryl, said cycloalkyl, aryl, heterocyolo and heteroaryl in turn is optionally substituted with alkyl or substituted alkyl; A is a bond, C.sub.1-4 alkylene, substituted C.sub.1-4 alkylene, --C(.dbd.O)NH--, --C.sub.1-4 alkylene-C(.dbd.O)NH--, or substituted C.sub.1-4 alkylene-C(.dbd.O)NH--; R.sub.17 and R.sub.18 are independently selected from hydrogen, alkyl, substituted alkyl, and aryl; and R.sub.17a is alkyl or substituted alkyl. 7. The compound of claim 6, or a pharmaceutically-acceptable salt or hydrate, thereof, in which A is --(CHR.sub.14).sub.m --(CR.sub.15 R.sub.16).sub.n -- or --(CHR.sub.14).sub.p --C(.dbd.O)NH--; R.sub.14, R.sub.15 and R.sub.16 at each occurrence are independently selected from hydrogen, alkyl, hydroxy, hydroxyC.sub.1-4 alkyl, C.sub.1-4 alkoxy, and phenyl, and/or one of R.sub.15 and one of R.sub.16 join together to form a 3 to 6 membered cycloalkyl; m and n are 0, 1 or 2; and is 0, 1, 2, or 3. 8. The compound of claim 6, or a pharmaceutially-acceptable salt or hydrate, thereof, in which R.sub.17 and R.sub.18 are independently selected from hydrogen, alkyl, phenyl, or benzyl wherein the phenyl or beazyl is optionally substituted with alkyl, hydroxy, or hydroxyalkyl. 9. The cornpoimd of claim 1, or pharmaceutically-aeceptable salt or hydrate, thereof, in which R.sub.1 cyano; R.sub.2 is hydrogen, alkyl, or benzyl; R.sub.3 is phenyl optionally substituted with C.sub.1-4 alkyl, halogen, mfluoromethyl, OCF.sub.3, cyano, nitro, amino, hydroxy, or methoxy; and R.sub.4 is halogen, alkyl, trifluoromethyl, or OCF.sub.3. 10. The compound of claim 1, or a pharmaceutically-acceptable salt or hydrate, thereof, in which R.sub.1 is C(.dbd.O)R.sub.9 ; R.sub.2 is hydrogen, alkyl, or benzyl; R.sub.3 is phenyl optionally substituted with C.sub.1-4 alkyl, halogen, trifluoromethyl, OCF.sub.3, cyano, nitro, amino, hydroxy, or methoxy; R.sub.4 is halogen, alkyl, trifluoromethyl, or OCF.sub.3 ; and R.sub.9 is --NR.sub.10 R.sub.11, alkyl or phenyl optionally substituted with one to four of halogen, cyano, trifluoromethyl, nitro, hydroxy, C.sub.1-4 alkoxy, haloalkoxy, C.sub.1-6 alkyl, CO.sub.2 alkyl, SO.sub.2 alkyl, SO.sub.2 NH.sub.2, amino, NH(C.sub.1-4 alkyl), N(C.sub.1-4 alkyl).sub.z, NHC(.dbd.O)akly, C(.dbd.O)alkyl, and/or C.sub.1-4 alkyl optionally substituted with one to three of trifluoromethyl, hydroxy, cyano, phenyl, pyridinyl; and/or a five or six membered heteroaryl or heterocylo in turn optionally substituted with keto or having a benzene ring fused thereto. 11. A compound having the formula: ##STR576## or a pharmaceutically-acceptable salt or hydrate thereof, wherein: ##STR577## R.sub.1 is cyano, --SO.sub.2 R.sub.8, --C(.dbd.O)R.sub.9, or heteroaryl; R.sub.2 is (i) independently hydrogen, alkyl, or subitituted alkyl, or (ii) taken together with R.sub.3 forms a heterocyclo; R.sub.3 is (i) independently selected from (a) alkyl optionally substituted with one to two of hydroxy and alkoxy; (b) alkylthio or aminoalkyl optionally substituted with hydroxy or alkoxy; (c) -A.sub.1 -aryl, wherein the aryl is optionally substituted with up to four substituents selected from alkyl, substituted alkyl, halogen, haloalkoxy, cyano, nitro, --NR.sub.17 R.sub.18, --SR.sub.17, --OR.sub.17, --SO.sub.2 R.sub.17a, --SO.sub.2 NR.sub.17 R.sub.18, --NR.sub.17 C(.dbd.O)R.sub.18, --CO.sub.2 R.sub.17, --C(.dbd.O)R.sub.17, cycloalkyl, aryl, heterocyclo, and heteroaryl, and/or has fused thereto a five or six membered cycloalkyl ring; (d) -A.sub.2 -heteroaryl wherein the heteroaryl is a five or six membered monocyclic ring having 1 to 3 heteroatoms selected from N, O, and S, or an eight or nine membered bicyclic ringed system having at least one aromatic ring and 1 to 4 heteroatoms selected from N, O, and S in at least one of the rings, said heteroaryl being optionally substituted with halogen. alkyl, alkoxycarbonyl, sulfonamide, nitro, cyano, trifluoromethyl, alkylthio, alkoxy, keto, --C(.dbd.O)H, acyl, benzyloxy, hydroxy, hydroxyalkyl, or phenyl optionally substituted with alkyl or substituted alkyl; (e) -A.sub.2 -hoterooyclo wherein the heterocyclo is optionally substituted with one to two groups selected from alkyl, keto, hydroxy, hydroxyalkyl, --C(.dbd.O)H, acyl, CO.sub.2 H, alkoxycarbonyl, phenyl, and/or benzyl, and/or has a bridged carbon--carbon chain or fused benzene ring joined thereto; (f) -A.sub.2 -cycloalkyl wherein the cycloalkyl is optionally substituted with one to two groups selected from alkyl, keto, --C(.dbd.O)H, acyl, CO.sub.2 H, alkoxycarbonyl, and/or benzyl, and/or has a bridged carbon--carbon chain or fused benzene ring joined thereto; or (ii) taken together with R.sub.2 forms a heterocyclo; R.sub.4 at each occurrence is selected independently of each other R.sub.4 from the group consisting of halogen, alkyl, haloalkyl, intro, cyano, and haloalkoxy; R.sub.7a, R.sub.7b and R.sub.7c are alkyl, carbamyl, or carbamylalkyl, or R.sub.7a and R.sub.7c join to form an aryl or heteoraryl; R.sub.8 is alkyl, arylalkyl, or aryl; R.sub.9 is alkyl, substituted alkyl, alkoxy, alkylthio, cycloalkyl, aryl, heteroaryl, heterocyclo, or CO.sub.2 R.sub.12 ; R.sub.10 is independently hydrogen, alkyl, or alkoxy; and R.sub.11 is independently hydrogen, alkyl, substituted alkyl, alkoxy heterocyclo cycloalkyl, aryl, or heteroaryl; or R.sub.10 and R.sub.11 taken together form a heterocyclo or heteroaryl optionally substituted with alkyl, keto, CO.sub.2 H, alkoxycarbonyl, hydroxy, alkoxy, alkyl, carbamyl, aryl, or substituted alkyl, wherein when the R.sub.10 and R.sub.11 group comprises a phenyl ring, said phenyl ring is optionally substituted with one to two of alkyl, halogen, and alkoxy; R.sub.12 is hydrogen or alkyl; A.sub.1 is --(CHR.sub.14).sub.m --V--(CR.sub.15 R.sub.16).sub.n -- or --(CHR.sub.14).sub.p --(C.dbd.O)NH--; A.sub.2 is --(CHR.sub.14).sub.m --V--(CR.sub.15 R.sub.16).sub.n ; V is a bond, S, or --NR.sub.22 --; R.sub.14, R.sub.15 and R.sub.16 at each occurrence are independently selected from hydrogen, alkyl, hydroxy, hydroxyC.sub.1-4 alkyl, C.sub.1-4 alkoxy, and phenyl, and/or one of R.sub.15 and one of R.sub.16 join together to form a three to six membered cycloalkyl; R.sub.17 and R.sub.18 are independently selected from hydrogen, alkyl, pheziyl, and benzyl, wherein the phenyl and benzyl is optionally substituted with alkyl, hydroxy, or hydroxyalkyl; R.sub.17a is alkyl or substituted alkyl; R.sub.22 is hydrogen or alkyl; m and n are 0, 1, 2, or 3; p is 0, 1, 2, or 3; and q is 0, 1, 2, or 3. 12. The compound of claim 11, or a pharmaceutically-acceptable salt or hydrate, thereof, having the formula: ##STR578## in which R.sub.7a, R.sub.7b and R.sub.7c are alkyl, carbamyl or carbamylC.sub.1-4 alkyl, or R.sub.7a and R.sub.7c join to form a fused phenyl ring; R.sub.23 is selected from hydrogen, alkyl, hydroxyulkyl, or phenyl; R.sub.24 is selected from alkyl, halogen, trifluoromethyl, cyano, halogen, hydroxy, OCF.sub.3, methoxy, phenyloxy, benzyloxy, cyano, acyl, or two R.sub.24 groups join to form a fused cycloalkyl or benzene ring; and x is 0, 1, or 2; and y is 0, 1, 2, or 3. 13. The compound of claim 12, or a pharmacentically-acceptable salt or hydrate, thereof, in which R.sub.1 is cyano or --C(.dbd.O)R.sub.9. 14. The compound of claim 13, or a pharmacentically-acceptable salt or hydrate, thereof, in which R.sub.9 is --NR.sub.10 R.sub.11, alkyl or phenyl optionally substituted with one to four of halogen, cyano, trifluoromethyl, nitro, hydroxy, C.sub.1-4 alkoxy, haloalkoxy, C.sub.1-6 alkyl, CO.sub.2 alkyl, SO.sub.2 alkyl, SO.sub.2 NH.sub.2, amino, NH(C.sub.1-4 alkyl), N(C.sub.1-4 alkyl).sub.2, NHC(.dbd.O)alkyl, C(.dbd.O)alkyl, and/or C.sub.1-4 alkyl optionally substituted with one to three of trifluoromethyl, hydroxy, cyano, phenyl, pyridinyl; and/or a five or six membered heteroaryl or heterocyclo in turn optionally substituited with keto or having abenzene ring fused thereto. 15. A non-peptidic organic compound according to claim 1, or a pharmaceutically-acceptable salt or hydrate, thereof, having less than 1000 molecular weight that is effective for inhibiting F.sub.1 F.sub.0 -ATP hydrolase. 16. A compound according to claim 15, or a pharmaceutically-acceptable salt or hydrate thereof; having less than 750 molecular weight. 17. A method of inhibiting F.sub.1 F.sub.0 -ATP hydrolase by administering to a mammal a non-peptidic organic compound according to claim 1, or a pharmaeutically-acceptable salt or hydrate thereof, having less than 1000 molecular weight. 18. The method of claim 17, comprising administering to the mammal the non-peptidic organic compound in combination with a second compound selected from propafenone, propranolol; sotalol, dofetilide, amiodarone, azimilide, ibutilide, ditiazem, verapamil, captopril, lisinopril, zofenopril, ramipril, fosinopril, enalapril, eranopril, cilazopril, delapril, pentopril, quinapril, omapatrilat, gemopatrilat, losartan, irbesartan, valsartan, sitaxsentan, atrsentan;verapamil, nifedipine, diltiazem, amlodipine and mybefradil, digitalis, ouabain, chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichloromethiazide, polythiazide, benzthiazide, ethacrynic acid tricrynafen, chlorthalidone, furosemide, musolimine, bumetanide, triamtrenene, amiloride, spironolatone, aplirinone, dipyridamole, cilostazol, sildenafil, ifetroban, picotamide, ketanserin, clopidogrel, picotamide, rosuvastaitin, atavastatin visastatin, questran, CP-529414, lovenox, enoxaparain dalteparinnadolol, carvedilol, albuterol, terbutaline, formoterol, salmeterol, bitolterol, pilbuterol, fenoterol, ipratropium bromide, metformin, acarbose, repaglinide, glimpepiride, glyburide, glyburide, glipizide, glucovance, troglitazone, rosiglitazone, pioglitazone, GLP-1, nefazodone, sertraline, diazepam, lorazepam, buspirone, hydroxyzine pamoate, acarbose, endostatin, probucol, BO-653, Vitamin A, Vitamin E, AGI-1067, alendronate, raloxifene, orlistate, cyclosperine A, paclitaxel, FK506, adriamycin, famotidine, rapitidine, ompeprazole, estrogen, estradiol, dipyridamole, cilostazol, sildenafil, ketanserin, taxol, cisplatin, paclitaxel, adriamycin, epothilones, carboplatin, cromolyn, nedocromil, theophylline, zileuton, zafirlukast, monteleukast, pranleukast, beclomethasone, triamcinolone, budesonide, fluticasone, flunisolidem prednisone; dexamethasone, etanercept, aspirin, indomethacin, pravastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin, AZ4522, itavastatin, ZD-4522, rosuvastatin, atavastatin, visastatin, abciximab, eptifibatide, tirofiban, clopidogrel, ticlopidine, CS-747, ifetroban, aspirin; cariporide, streptokinase, reteplase, activase, lanoteplase, urokinase, prourokinse, tenecteplase, lanoteplase, anistreplase, eminase, lepirudin, argatroban, XR-330, T686, anti-.alpha.-2-antiplasmin antibody, and doesdipyridanmol. 19. A pharmaceutical composition comprising at least one compound of claim 1 and a pharmaceutically-acceptable carrier or diluent. 20. The pharmaceutical composition of claim 19 further comprising at least one additional therapeutic agent selected from one or more of propafenone, propranolol; sotalol, dofetilide, amiodarone, azimilide, ibutilide, ditiazem, verapamil, captopril, lisinopril, zofenopril, ramipril, fosinopril, enalapril, ceranopril, cilazopril, delapril, pentopril, quinapril, omapatrilat, gemopatrilat, losartan, irbesartan, valsartan, sitaxsentan, atrsentan;verapamil, nifedipine, diltiazem, amlodipine and mybefradil, digitalis, ouabain, chlorothiazide, hydrochlorothiazide, flumethiazide, hydroflumethiazide, bendroflumethiazide, methylchlorothiazide, trichloromehtiazide, polythiazide, benztiazide, ethacrynic acid tricrynafen, chlorthalidone, furosemide, musolimine, bumetanide, triamtrenene, amiloride, spironolatone, aplirinone, dipyridamole, cilostazol, sildenafil, ifetroban, picotamide, kentanserin, clopidogrel, picotamide, rosuvastatin, atavastatin visastatin, questran, CP-529414, lovenox, enoxaparain dalteparinnadolol, carvedilol, albuterol, terbutaline, formoterol, salmeterol, bitolterol, pilbuterol, fenoterol, ipratropium bromide, metformin acarbose, repaglinide, glimpepiride, glyburide, glipizide, glucovance, troglitazone, rosiglitazone, pioglitazone, GLP-1, nefazodone, sertraline, diazepam, lorazepam, buspirone, hydroxyzine pamoate, acarbose, endostatin, probucol, BO-653, Vitamin A, Vitamin E, AGI-1067, alendronate, raloxifene, orlistate, cyclosporine A, paclitaxel, FK506, adriamycin, famotidine, ranitidine, ompeprazole, estrogen, estradiol, dipyridamole, cilostazol, sildenafil, ketanserin, taxol, cisplatin, paclitaxel, adriamycin, epothilones, carboplatin, cromolyn, nedocromil, theophylline, zileuton, zafirlukast, monetleulast, pranlikast, beclomthasone, triamcinolone, budesonide, fluticasone, fluticasone, flunisolide, prednisone; dexamethasone; etanercept, aspirin, indomethacin, pravastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin, AZ4522, itavastatin, ZD-4522, rosuvastatin, atavastatin, visastatin, abciximab, eptifibatide, tirofiban, clopidogrel, ticlopidine, CS-747, ifetroban, aspirin; cariporide, streptolinase, reteplase, activase, lanoteplase, urokinase, prourokinse, tepecteplase, lanoteplase, anistreplase, eminase, lepirudin, argatroban, XR-330, T686, anti-.alpha.-2-antiplasmin antibody, and doesdipyridanmol. 21. The pharmaceutical composition of claim 20 wherein the additional therapeutic agent is an anti-arrnyhthmic agent selected from sotalol, dofetilide, amiodarone, azimilide, ibutilide, diltiazem, and verapamil. 22. The pharmaceutical composition of claim 20 wherein the additional therapeutic agent is an anti-hypertensive agent selected from captopril, lisinopril, zofenopril, ramipril, fosinopril, enalapril, ceranopril, cilazopril, delapril, pentopril, quinapril, omapatrilat, gemopatrilat, losartan, irbesartan, valsartan; sitaxsentan, and atrsentan. 23. The pharmaceutical composition of claim 20 wherein the at least one additional therapeutic agent is a platelet inhibitor selected from one or more of abciximab, eptifibatide, tirofiban, clopidogrel, ticlopidine, CS-747, ifetroban, and aspirin. 24. A method of treating an ischemic condition comprising administering an effective amount of at least one compound of claim 1 to a patient in need thereof wherein the ischemic condition is an acute coronary syndrome selected from myocardial infarction, congestive heart failure, and cardiac arrhythmias. 25. A method of inhibiting mitochondrial F.sub.1 F.sub.0 ATP hydrolase activity comprising administering an effective amount of at least one compound of claim 1 to a patient in need thereof.

Details for Patent 6,916,813

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2021-12-10
Genentech, Inc.	ACTIVASE	alteplase	For Injection	103172	11/13/1987		2021-12-10
Genentech, Inc.	CATHFLO ACTIVASE	alteplase	For Injection	103172	09/04/2001		2021-12-10